{"id":479785,"date":"2020-04-16T18:10:01","date_gmt":"2020-04-16T18:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=479785"},"modified":"2020-04-16T18:10:01","modified_gmt":"2020-04-16T18:10:01","slug":"adrenoleukodystrophy-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-epidemiology-forecast-to-2030_479785.html","title":{"rendered":"Adrenoleukodystrophy Epidemiology Forecast to 2030"},"content":{"rendered":"
\"Adrenoleukodystrophy<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Adrenoleukodystrophy Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity.<\/p>\n

The disease mainly affects males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may be clinically affected as well.<\/p>\n

The main neurological manifestations include a progressive, fatal, inflammatory cerebral leukodystrophy (cerebral adrenoleukodystrophy) most frequently appearing in young boys, and a slowly progressive, non-inflammatory axonal myelopathy and peripheral neuropathy (adrenomyeloneuropathy, AMN), that occurs in most adult males. Many females develop myeloneuropathy as well, but usually at a later stage and with milder symptoms than seen in males. Furthermore, the disorder manifests with primary adrenal failure (PAI) in more than half of the males that are usually not seen in females.<\/p>\n

The DelveInsight Adrenoleukodystrophy epidemiology report<\/strong> gives a thorough understanding of the Adrenoleukodystrophy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Adrenoleukodystrophy in the US, Europe, and Japan. The report covers the detailed information of the Adrenoleukodystrophy epidemiology scenario in seven major countries (US, EU5, and Japan).<\/p>\n

 <\/p>\n

Key Highlights Of The Report<\/strong><\/p>\n

In 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242.<\/p>\n

The estimates show the highest diagnosed prevalence of Adrenoleukodystrophy in the United States with 4,885 cases in 2017.<\/p>\n

Among the European 5 countries, Germany had the highest diagnosed prevalent population of Adrenoleukodystrophy, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population.<\/p>\n

As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017–2030).<\/p>\n

 <\/span><\/span><\/p>\n

Request for Sample Pages: <\/span><\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/adrenoleukodystrophy-epidemiology<\/a><\/strong><\/p>\n

 \"Adrenoleukodystrophy<\/p>\n

Adrenoleukodystrophy Epidemiology<\/span><\/a><\/strong><\/p>\n

Delveinsight’s Adrenoleukodystrophy epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. <\/span><\/p>\n

The Adrenoleukodystrophy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. <\/span><\/p>\n

The Adrenoleukodystrophy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. <\/span><\/p>\n

It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.<\/span><\/p>\n

 <\/span><\/span><\/p>\n

Scope of the Report<\/strong><\/p>\n